Clinical trial data does not lie. Tirzepatide delivered 20.2% average body weight loss versus 13.7% with semaglutide in the 72-week SURMOUNT-5 head-to-head trial.
At Nexus Clinic KL, medically supervised Mounjaro and Zepbound programmes are structured around the right dose, monthly monitoring, and lifestyle support that fits real Malaysian life. This is evidence-led weight management with proper medical assessment, dose titration oversight, and long-term planning.
Tirzepatide Programme
20.2% avg weight loss • Dual GIP/GLP-1
NPRA approval dated 30 August 2025
First-in-class twincretin approach for appetite and blood sugar control
Complimentary consultation, titration support, and monthly reviews
Wisma UOA II, Jalan Pinang — easily accessible
All programmes include full medical assessment and ongoing support
Learn more about our processFor a patient weighing 100 kg, the difference between 20.2% and 13.7% total body weight loss is the difference between losing about 20 kg and losing 13.7 kg. That is why tirzepatide has become the most powerful injectable option currently discussed for chronic weight management in Malaysia.
Mounjaro is the diabetes indication for tirzepatide. Zepbound is the weight management indication for the same molecule, subject to import and clinic availability. Nexus Clinic KL supports both pathways through a structured programme designed around assessment, safety, titration, monitoring, and realistic daily adherence.
Tirzepatide is an injectable prescription medication approved for type 2 diabetes and chronic weight management. It is the first and only dual-action twincretin that activates both GIP and GLP-1 receptor pathways rather than the single GLP-1 pathway used by older medicines such as Ozempic and Wegovy.
In simple terms, tirzepatide helps people feel full sooner, stay satisfied for longer, reduce appetite between meals, and improve blood sugar control through two complementary hormone pathways at the same time.
Both products contain the same Eli Lilly tirzepatide molecule and use the same once-weekly KwikPen injection device.
Mounjaro is registered for type 2 diabetes management. Zepbound refers to the chronic weight management indication and may be available subject to import logistics and clinic supply.
At Nexus Clinic KL, your doctor confirms which treatment route is appropriate, what stock is available through proper channels, and what plan best matches your health profile.
The GLP-1 component slows digestion, sends fullness signals to the brain, reduces appetite, and stimulates insulin secretion when blood sugar rises. The GIP component works through a different incretin pathway to improve insulin sensitivity, enhance fat metabolism, and amplify the overall weight loss effect.
What patients commonly notice in real life:
Tirzepatide is not just about willpower. It changes the biological signals that drive hunger, fullness, metabolism, and glucose regulation.
Eligibility is determined by a doctor, but tirzepatide for chronic weight management is generally indicated for adults with:
A full medical assessment still matters because suitability, safety, current medications, and contraindications all need to be reviewed before any prescription is issued.
You should not use tirzepatide if:
You need careful assessment if you have a history of:
A proper clinic does not just prescribe an injection. It screens risk, confirms eligibility, teaches safe use, and monitors progress responsibly.
SURMOUNT-1 showed average weight loss of 15.0% at 5mg, 19.5% at 10mg, and 20.9% at 15mg over 72 weeks. In SURMOUNT-5, tirzepatide delivered 20.2% average body weight loss compared with 13.7% for semaglutide over the same period.
For most patients, the practical journey follows this pattern:
Loading dose phase with body adjustment and early appetite reduction
Therapeutic effect becomes clearer and meaningful loss often begins
Dose optimisation, stronger control, and more visible body composition change
Maintenance planning matters because sustained outcomes matter more than short bursts
The aim at Nexus Clinic KL is not rapid, unmanaged loss. The aim is safe, evidence-based, and sustainable progress.
Every patient is different, but the programme follows a structured medical pathway from consultation through maintenance.
Health history, BMI, blood pressure, current medications, blood markers where relevant, and suitability review before anything is prescribed.
Your doctor may review:
Patients are taught once-weekly self-injection into the abdomen, thigh, or upper arm, plus practical support around meals, work schedules, family eating patterns, and realistic adherence.
The goal is not a paper-perfect plan. The goal is a plan that works in real life.
Follow-ups monitor weight, side effects, blood pressure, blood sugar where relevant, and the next titration step. As goals are reached, maintenance may include dose reduction, closer lifestyle support, or a reduced long-term therapeutic dose.
Slide to see the incredible transformations achieved by our clients
Drag to compare
Drag to compare
Drag to compare
Results may vary. Individual results depend on various factors.
Start Your TransformationGastrointestinal effects are the most common and are usually most noticeable during each dose escalation step. This is one reason slow titration matters.
The most common side effects of tirzepatide include nausea, constipation, diarrhoea, reduced appetite, and changes in bowel habit. These are dose-dependent and often improve within two to four weeks after each escalation step.
Patients who increase too quickly usually feel more discomfort. Patients who titrate slowly are more likely to tolerate the programme well and stay on track.
Serious but uncommon risks include pancreatitis, acute gallbladder disease, severe dehydration, significant hypoglycaemia when combined with certain diabetes medicines, thyroid-related warnings, and allergic reactions.
This is why medical monitoring is not optional. It is part of the treatment itself.
Because GLP-1 related medicines can delay gastric emptying, patients scheduled for surgery, general anaesthesia, or deep sedation should inform both the prescribing doctor and the anaesthesia team early.
Procedure planning should always be individualised when a patient is using tirzepatide or similar medications.
Pricing depends on dose, monitoring structure, and whether the plan is a simple monthly prescription pathway or a more comprehensive package with bloods and check-ins included.
Typical pricing factors include:
Indicative pricing from the source content:
2.5mg starter from RM 1,100 to RM 1,500, 5mg from RM 1,200 to RM 1,800, 10mg from RM 1,800 to RM 2,800, 15mg from RM 2,200 to RM 3,500, and 3-month packages from RM 4,500 to RM 9,000.
Same tirzepatide molecule, same once-weekly device, different approved indication and availability pathway.
Choice still depends on your indication, medical history, side effect tolerance, blood sugar profile, availability, and doctor guidance.
Yes, it can be combined with lifestyle modification, dietary coaching, and selected non-pharmacological body contouring treatments for appropriate patients.
Treatments such as fat freezing or CoolSculpting target localised fat pockets and are not substitutes for systemic appetite and metabolic treatment.
For many patients, the right order is medical weight loss first, then body contouring later once overall weight is improving and expectations are clearer.
Medication works best when the treatment window is used to build habits that support long-term metabolic health and reduce rebound weight gain after the active phase.
Practical habits that matter:
Protein-focused meals to improve fullness
Hydration support during nausea or constipation phases
Smaller meals while appetite signals are changing
Light activity to protect muscle, insulin sensitivity, and mood
Better sleep because poor sleep worsens hunger regulation
The goal is sustainable fat loss and metabolic improvement, not burnout from crash dieting.
Common patient questions before starting a tirzepatide programme.
Both contain the same tirzepatide molecule at the same doses using the same KwikPen device. The main difference is the approved indication and availability pathway.
In SURMOUNT-1, average loss over 72 weeks was 15.0% at 5mg, 19.5% at 10mg, and 20.9% at 15mg. Individual results vary by dose reached, adherence, starting weight, and lifestyle changes.
Yes. Mounjaro received NPRA approval in Malaysia on 30 August 2025 and is prescription-only. Tirzepatide should be sourced only through licensed clinics and verified supply channels.
It activates both GLP-1 and GIP receptor pathways, combining delayed gastric emptying, fullness signalling, improved insulin response, and better insulin sensitivity.
Adults with BMI 30 or above, or BMI 27 or above with at least one weight-related condition, may be eligible after full medical assessment.
Nausea, constipation, diarrhoea, and reduced appetite are among the most common effects, especially during dose escalation. Slow titration helps reduce discomfort.
SURMOUNT-5 reported 20.2% average weight loss with tirzepatide versus 13.7% with semaglutide over 72 weeks, showing stronger weight loss performance in that direct comparison.
It can be combined with lifestyle support and selected non-pharmacological body contouring treatments for suitable patients, but the order and safety plan should be doctor-led.
Duration depends on your goals, your response, and how well long-term lifestyle and maintenance strategies are established. Obesity management is usually not a short-term issue.
SURMOUNT-4 showed that patients who stopped tirzepatide regained a meaningful portion of lost weight, which is why maintenance planning should be built into the programme from the start.
Long-term safety has been studied across the SURMOUNT and SURPASS programmes, with generally well-tolerated results when treatment is prescribed appropriately and monitored properly.
It is taken once weekly by subcutaneous injection using the KwikPen into the abdomen, thigh, or upper arm, with the dose usually increased every four weeks as tolerated.
1. Clear evidence on mechanism, outcomes, and the difference between Mounjaro, Zepbound, Wegovy, and Ozempic.
2. Honest explanation of eligibility, contraindications, side effects, and why medical supervision matters.
3. Practical clarity on dose escalation, maintenance, pricing, and how a real clinic pathway works from first consultation onward.
The page should keep emphasising the strengths already built into the programme:
These are the details that make the page feel medically credible, useful, and conversion-ready.
Start with a complimentary consultation and get a clear answer on suitability, dosage pathway, expected results, and the right medically supervised plan for you.
Book Free Consultation